OHIO

Ohio State University

For further information on any of the clinical trials please visit: http://vet.osu.edu/vmc/clinical-trials OR contact

An Exploratory Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Lymphoma

Study Details:

Especies: dogs

Tumor type: Lymphoma

Purpose of Study: The purpose of this study is to evaluate the safety and antitumor activity of KPT-335 in dogs with lymphoma, either newly diagnosed or in first relapse after completion of a single chemotherapy protocol (multi-agent or single agent).

A study of KPT-335 was performed in dogs with cancer and the dose of 1.5 mg/kg was found to be well-tolerated over 4-20 weeks of dosing when given on a Monday/Wednesday/Friday (MWF) basis.  In dogs with lymphoma, partial shrinkage of lymph nodes and stable disease were noted in over half of the patients treated.  Side effects from KPT-335 given at this dose on a MWF basis included mild loss of appetite, occasional vomiting, and diarrhea, with some dogs experiencing an increase in thirst and an increase in urination.  All of these side effect were mild and well-controlled with additional medications.

Palladia or Palladia plus Radiation Therapy in Cats with Oral Squamous Cell Carcinoma

Study Details:

Especies: cats

Tumor type: Oral Squamous Cell Carcinoma

Purpose of Study: The purpose of this study is to identify the activity of toceranib phosphate (Palladia) alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma. Inclusion Criteria:

• Have histologically or cytologically confirmed diagnosis of oral SCC
• Have a life expectancy of at least 6 weeks
• Have no evidence of metastatic disease at the time of enrollment
• Have no other serious health problems that are incompatible with the study (as renal, cardiac or hepatic insufficiency)

A Pilot Study of Vinblastine/Palladia Therapy for Canine Transitional Cell Carcinoma

Study Details:

Especies: dogs

Tumor type: Transitional Cell Carcinoma

Purpose of Study: The goal of this study is to assess efficacy of Palladia and Vinblastine combined for treatment of canine transitional cell carcinoma and to compare computerized tomography and ultrasound for measurement of tumor response.

The two drugs to be combined in this clinical trial are vinblastine, a chemotherapy agent used to treat several different cancers in dogs, and Palladia, an oral drug that works by blocking the signaling of several receptors, including VEGFR2 and PDGFR.  Both VEGFR2 and PDGFR are important in permitting the growth of new blood vessels, so Palladia works to slow down or block the growth a blood supply into tumors and prevent them from continuing to grow.  There is preliminary evidence that both vinblastine and Palladia may each have some activity against TCC in dogs.  A recent pilot study demonstrated that 36% of dogs with TCC given vinblastine had their tumor shrink partially following treatment and another 50% had their tumors stop growing for a period of time.  In previous work with Palladia, 3 of 4 dogs treated with drug had their tumors stop growing for a period of time.  Vinblastine and Palladia have recently been combined together in a clinical trial to determine how best to use these drugs together in the setting of mast cell cancer.  This study identified the dose of vinblastine and Palladia  that could be safely combined over multiple treatments.  These doses will be used in the current study.

Kit mutation and localization status as response predictors in canine mast cell tumors treated with toceranib or vinblastine: A multi-center response-adaptive randomized trial

Study Details:

Especies: dogs

Tumor type: Mast Cell Tumor

Purpose of Study: The goal of this study is to determine if canine mast cell tumors with kit mutation respond better to Palladia and whether screening for kit mutations play a role in treatment decision-making. Dogs with MCT will undergo screening including complete blood count, chemistry panel, urinalysis and abdominal ultrasound to determine eligibility for the study.  A baseline tumor biopsy will then be obtained if my dog is found to be eligible.  Following biopsy, your dog will receive Benadryl, prilosec, and prednisone for at least 72 hours prior to treatment with either vinblastine or Palladia.  The determination of treatment protocol will be made by study personnel at Colorado State University.  If your dog has been assigned to receive vinblastine, the drug will be administered by intravenous injection once per week for 4 weeks, then every other week for another 4 treatments (total of 8 treatments).  If your dog has been assigned to receive Palladia, the drug will be administered orally on Monday, Wednesday, and Friday every week for a total of 3 months.  If progressive disease is noted during the planned treatments, then your dog will be removed from the study and other therapies will be offered.  Dogs in either treatment arm will be evaluated weekly for the first 4 weeks, then every other week for the next 8 weeks.

Pulse Toceranib plus Lomustine for the Treatment of Unresectable Canine Mast Cell Tumors: A Multicenter Study Led by Colorado State University

Study Details:

Especies: dogs

Tumor type: Mast Cell Tumor

Purpose of Study: This study is a multi-center effort led by Dr. Doug Thamm at Colorado State University to determine the maximum tolerated dose, tolerability and adverse effect profile of combined treatment with pulse-dose toceranib and lomustine in dogs with MCT. He also would like to determine the response rate and progression-free interval in dogs with measurable MCT treated with combined pulse-dose toceranib and lomustine. If, upon evaluation, the dog meets eligibility criteria, the owner must complete an Owner Consent Form of their pet’s initial clinical appearance. For baseline status, blood and urine will be sampled; target tumors identified, measured. Also thoracic radiographs and/or abdominal ultrasound will be performed, as well as, tumor and skin biopsies.

 

COTC007b: Preclinical Comparison of Three Indenoisoquinolines Candidates in Tumor-Bearing Dogs

 Study Details:

Especies: dogs

Tumor type: Lymphoma

Purpose of Study: The purpose of this trial evaluating three structurally related chemotherapy drugs to to define their safety, pharmacokinetics, and pharmacodynamic modulation.

 

Evaluation of KUN C01 in dogs with spontaneous solid tumors

Study Details:

Especies: dogs

Tumor type: Mast Cell Tumor

Purpose of Study: The primary objective of this clinical trial is to evaluate the safety and tolerability of KUN C01 given to dogs with solid tumors (carcinomas, sarcomas, mast cell tumors, melanomas) and the secondary objective is to describe the antitumor response in tumor-bearing dogs.

Contact Information for this trial: Dr. Francisco Clemente Vicario Email: Phone 614-688-5713 or 614-247-870